Oncast Money · Money Tonight

October CPI cool-down forecast

Nov 10, 2026, 1:12 AM UTC · Fact-checked before it aired. Unconfirmed claims from this segment are not shown.

Nvidia's board said Sunday it would investigate CEO Jensen Huang over his relationship with Alice Huang, a former Megaspeed executive U.S. intelligence reportedly assessed as a Chinese intelligence asset. On Monday, Nvidia shares fell $7.97, or 4.27%, to $178.67, erasing about $190 billion in market value. The first shareholder class action was filed Monday in federal court in San Jose, California, on behalf of investor Mark Kistenmacher. The proposed class covers buyers of Nvidia securities from Oct. 9, 2025, through Nov. 8, 2026.

The suit claims Nvidia and Huang misled investors by denying anything unusual about Nvidia's interactions with Megaspeed and Alice Huang, while Huang later acknowledged an intimate relationship. The alleged spy link raised national-security concerns and fears about chip diversion; when the probe and lawsuit emerged, the stock dropped.

Nvidia and CEO Jensen Huang were sued Monday in a proposed shareholder class action alleging they concealed Huang's relationship with Alice Huang, a suspected Chinese intelligence asset; Nvidia stock closed down about 4.3%.

Karyopharm Therapeutics, the maker of Xpovio/selinexor, filed for Chapter 11 bankruptcy protection on Nov. 2, 2026, and announced a proposed merger with Ayrmid Ltd. This is a corporate-deal roundup, not a single checkable factual claim.

The Pharma Letter reported the same Karyopharm Chapter 11 filing and proposed Ayrmid merger, backed by up to $55 million in new financing.

CNBC reports that prediction-market traders price relatively low odds that Nvidia CEO Jensen Huang exits in the near term after the probe. This is Goldman CEO David Solomon's opinion/statement about AI financing appetite, not a verifiable factual claim.

Fact-check

VERIFIED TRUE

JUST IN: 🇺🇸🇨🇳 Nvidia $NVDA and CEO Jensen Huang sued for allegedly defrauding shareholders by hiding ties to a Chinese spy.
Original post · Watcher.Guru (@WatcherGuru)

Reuters via [investing.com](https://www.investing.com/news/stock-market-news/nvidia-ceo-huang-sued-over-disclosures-related-to-suspected-chinese-spy-5013619) NA

VERIFIED TRUE

🚨 Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on November 2, 2026, and announced a proposed merger with Ayrmid Ltd. #mmsm #myeloma #MedEd #medtwitter #USMIRC @USMIRCNEWS @OpenMedKate @Larvol @US_HMC @oncodaily https://t.co/mgaJoxh3m7
Original post · Al-Ola A Abdallah MD (USMIRC) (@Abdallah81MD)

The Pharma Letter NAMES: Karyopharm Therapeutics = biopharma company; Xpovio = selinexor; Ayrmid Ltd = owner of GamidaCell POST 2119819772175000048: NOCLAIM N/A

VERIFIED TRUE

The Pharma Letter reported the same Karyopharm Chapter 11 filing and proposed Ayrmid merger, backed by up to $55 million in new financing.

Chapter 11, then a merger: Xpovio (selinexor) maker @Karyopharm has filed for bankruptcy protection under a restructuring plan to merge with Ayrmid, owner of @GamidaCellTx, backed by up to $55 million of new financing. https://t.co/1VbyVb5hmC #Biotech #Oncology
Original post · The Pharma Letter (@ThePharmaLetter)

The Pharma Letter NAMES: Karyopharm Therapeutics = Xpovio maker; Ayrmid = owner of GamidaCell

VERIFIED TRUE

Jensen Huang exit odds are low on prediction markets after Nvidia probe - Prediction markets traders price relatively low odds that the Nvidia CEO will depart in the near term.
Original post · CNBC

[cnbc.com](https://www.cnbc.com/2026/11/09/jensen-huang-nvidia-exit-prediction-markets.html) NAMES: Jensen Huang = Nvidia CEO POST news:2f74281a77064951: NOCLAI

Sources

What the hosts said

ATomorrow morning we get October inflation, and Wall Street expects a real cool-down.

B"Expects" is doing a lot of work. Prices still go up, just not as fast.

AWalter Bloomberg on X posted the consensus: headline CPI up 0.23 percent, from 0.65 in September.

BCore is forecast at 0.22, down from 0.33. The Fed's preferred core PCE is expected at 0.23.

ASo across the board, cooler.

BIf it holds. September caught everyone off guard. October could too.

ABut shelter costs are cooling, and shelter is the biggest part of the index.

BWe've been waiting for shelter to cool for two years. I'll believe it in the actual print.

AThe range across bank forecasts is narrow. Nobody is calling for a hot number.

BThat's what worries me. When everyone leans one way, the surprise risk is higher.

AYou sound like a trader.

BFormer life. Never leaves you.

AThe bank forecasts are just that — forecasts. We get the real number tomorrow at 8:30.

BIf it's soft, the rate-cut bets get louder. If not, the market has a problem.

AThat's why nobody should trade off a preview. But it's the biggest data point this week.

BOn to something even more speculative.

BDifferent world entirely. One post on X claims 21 banks plan a joint U.S. dollar stablecoin by early 2027.

ATwenty-one banks, one coin?

BJason Bassler on X lists Citi, Wells Fargo, Deutsche Bank, Bank of America, Goldman. His line: "Same gatekeepers. New stablecoin."

AThat's an unverified claim. No bank has confirmed it. But the idea is out there, so let's argue about it.

BIf true, it's the banks' answer to Tether and Circle. A dollar stablecoin with real bank backing and regulators.

AThat's not an answer. The whole point was to bypass the gatekeepers. Now they put on a new coat and call it innovation.

BNo, come on — this is exactly what brings crypto into the real economy. Banks have the trust and the rails.

ATrust? The same banks that needed bailouts? They'll own the coin, set the fees, freeze your account.

BSo you'd rather trust an offshore stablecoin issuer with no audits? That's what we had.

AI'd rather have competition. Twenty-one banks pooling into one coin is not competition, it's a club with a shared ledger.

BA club. You keep using that word.

AIt's a polite word for consortium. They're not doing this to save you money.

BThey're doing it because stablecoins already move trillions. If they don't, banks lose the payment layer.

AExactly — defensive. That tells you crypto already won the argument about speed.

BOr it tells you banks can still win on trust. We'll see which one matters more.

AAnd you think regulators will just wave it through? They've been fighting stablecoin issuers for years.

BActually, this is the version Washington can live with. Bank-issued, fully reserved, transparent.

A"Fully reserved" is doing a lot of work until you see the fine print.

BThat's why I said if true. But the concept is not a joke.

AFirst, let's see if the story itself is true. Right now it's one post and a lot of speculation.

BFair. But it's the best fight of the week.

ADifferent corner of the market, and this one is confirmed. Karyopharm Therapeutics filed for Chapter 11 in November 2026.

BThe maker of Xpovio, a blood cancer drug. The Pharma Letter posted on X about a restructuring plan to merge with Ayrmid.

AThe reported plan comes with up to 55 million dollars in new financing. The reported structure is a pre-packaged bankruptcy, not a fire sale.

BStill, old shareholders usually get wiped out. Bankruptcy after a promising drug? That stings.

ABiotech is brutal. One drug, high costs, a binary outcome. The company couldn't carry the debt.

BThat's the reality of the sector. It's not a scandal, just the model breaking under its own weight.

AThe new owner sees value in the drug. That's why the financing is there.

BExactly — the asset survives, the old equity doesn't. Promising science and a safe stock are not the same thing.

AAnd that's the last word on that one.

Cite this story as https://oncast.fm/story/1794273143923-money-segment-october-cpi-cool-down-forecast. Fact-check by Oncast. Cite the original sources above too.

Listen live on Oncast